



MEDICINES DISCOVERY AWARD PROGRAM

Executive Summary

About

Empire Discovery Institute (EDI) is a non-profit New York drug discovery and development accelerator created to translate promising scientific discoveries into new break-through treatments and cures, support vital upstate NY pharmaceutical research efforts, and foster the development of a vibrant biotech start-up community within New York State. Company CEO Martin Graham has assembled a world-class team of scientific, technical and business development veterans to its Scientific Advisory Board who have an established track record of translating discoveries through the early stages of development to clinical proof of concept and commercialization. EDI serves as an important bridge across the “valley of death” which has traditionally divided academic innovation from commercial translation. EDI has been made possible through an Empire State Development seed grant from New York State and through a research partnership with the University of Rochester, University at Buffalo, and Roswell Park Comprehensive Cancer Center.

Medicines Discovery Award Program (MDAP)


EDI's Medicines Discovery Award Program is a competitive incubator and accelerator program designed to identify and advance promising early stage drug discovery programs to initial proof of concept for commercialization. Successful projects will exit the program as either a licensing transaction to a strategic pharmaceutical partner or as an EDI-created startup company.

Funding and Support – Accepted projects will potentially be eligible to receive:

- Between \$250,000 and \$7.5M in total program support over five years, reviewed annually (includes salary, fringe benefits and cost of materials)
- Access to EDI's Scientific Advisory Board, strategic partners and consultant network
- Drug discovery and development expertise
- Project management and planning
- Business development and product commercialization
- Company incorporation and management
- Clinical development strategy, intellectual property, regulatory strategy, and IND preparation
- External program financing through venture capital or strategic pharma investments

The Scientific Advisory Board will evaluate the applications and determine which investigators will receive invitations into the oral presentation stage. The selected investigators will be asked to give a 30 minute oral presentation to the Scientific Advisory Board followed by a 30 minute Q&A session. Invitations into the Medicines Discovery Award Program will be extended in writing after a final Scientific Advisory Board review.

Stages of Discovery & Development



Programs of Interest

EDI is open to applications across a wide range of therapeutic areas providing a strong scientific, medical and commercial rationale can be made. Preferred programs have a clear mechanism of action or possess a well-defined genetic basis for the underlying condition. Programs with a strong biomarker component are highly desirable. Programs in the fields of cancer, neurological diseases/CNS conditions and platform technologies with therapeutic potential across multiple diseases are of particular interest. Investigators working in the rare and orphan diseases are also encouraged to apply. EDI is interested in programs that provide novel insights into the pathways and molecular determinants of human disease. We do not currently support the development of diagnostic products or medical devices.

Eligibility:

Investigators must hold a full-time faculty position at the University of Rochester, University at Buffalo or Roswell Park Comprehensive Cancer Center.

How to Apply:

Visit <https://www.discoveredi.org/award-details>

Contact:

Molly Mesko
Director of Portfolio Development & Alliance Management
meskom@discoverEDI.org